2020 IPO

Revolution Medicines Stock

Clinical-stage oncology therapeutics company

Sign up today and learn more about Revolution Medicines Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.

About Revolution Medicines Stock

REVOLUTION Medicines is a clinical-stage company involved in the discovery and development of precise small molecule therapeutics designed to translate frontier oncology targets within notorious pathways to outsmart cancer. It possesses oncology drug discovery capabilities built upon scientific knowledge of the biology of cancer pathways and proprietary technologies that enable the creation of small molecules that target atypical drug binding sites.

Funding History

February 2015$45.0M
December 2016$25.0M
April 2018$56.0M
July 2019$100M


Senior Vice President Human Resources

Luan M. Wilfong

Co-founder and Chief Scientific Officer

David L. Pompliano


Ryan Martins

Chief Operating Officer

Margaret Horn

SVP Clinical Development

Xiaolin Wang

Founding President & Chief Executive Officer

Mark A. Goldsmith

Founder & Scientific Advisory Board Chairman

Martin D. Burke

President of Research and Development

Steve Kelsey

EquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.

Some data provided by Crunchbase

Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As: